Professor Kirchhof has published over 300 papers in biomedical journals such as the Lancet, BMJ, Circulation, JACC, European Heart Journal, the Journal of Experimental Medicine, Nature Methods, or the Journal of Clinical Investigation.
He started his research career during a research year at Georgetown University, Washington DC, USA. At the University of Münster, where he trained and worked as a cardiologist and cardiovascular researcher, his translational cardiovascular research cluster worked on molecular mechanisms of heart disease with a special interest in sudden death and atrial arrhythmias. In parallel, he has initiated investigator-initiated controlled clinical trials to translate pathophysiological insights into new therapies for heart disease. He leads several investigator-initiated clinical trials as Chief Investigator and sits on other trials as a committee member.
The work of Professor Kirchhof is currently centred on deciphering the mechanisms causing atrial fibrillation and sudden death in a translational approach spanning wet lab research, team science, analyses of clinical registries, and controlled clinical trials. The ultimate aim of "team science", his partners in Birmingham and his wider network of research partners is to develop tools for a personalised approach to prevention and therapy of patients with heart diseases, especially to prevent AF and its complications, and to prevent sudden death.
A main funder of Professor Kirchhof is the British Heart Foundation, but Professor Kirchhof’s research is also supported by the Leducq Foundation and the German Centre for Heart Research (DZHK).
Look out for job opportunities if you have an interest in the field!
Find out more